Diabetes drug repurposed to fight polycystic kidney disease
NCT ID NCT06391450
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 trial tests whether empagliflozin, a diabetes drug, can safely slow kidney growth and preserve kidney function in 44 adults with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Participants take either empagliflozin or a placebo for 18 months, and some also take the standard drug tolvaptan. The goal is to see if adding empagliflozin helps protect the kidneys.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin
What this could lead to
If it works, this could offer a new way to slow kidney enlargement and preserve kidney function in people with polycystic kidney disease.
What could go wrong
This is a small, early-phase trial with only 44 participants, so results may not apply to everyone. The drug may not show a clear benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany